Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenecteplase bridging therapy before transfer for late-window MCA large-vessel occlusion stroke
ChiCTR2600135755Phase 3Not yet recruiting
- Sponsor
- Fujian Medical University Union Hospital
- Start
- Oct 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tenecteplase in ischemic stroke (2 arms), sponsored by Fujian Medical University Union Hospital. Primary endpoint: Proportion of participants with a favorable functional outcome at 90 days. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
tenecteplase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR2600135755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135755.